Last reviewed · How we verify

placebo to metronidazole

Merck Sharp & Dohme LLC · Phase 3 active Small molecule

placebo to metronidazole is a nitroimidazole antibiotic Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Amoebiasis, Bacterial vaginosis, Gastrointestinal infections.

Metronidazole is an antibiotic that works by stopping the growth of bacteria and protozoa.

Metronidazole is an antibiotic that works by stopping the growth of bacteria and protozoa. Used for Amoebiasis, Bacterial vaginosis, Gastrointestinal infections.

At a glance

Generic nameplacebo to metronidazole
SponsorMerck Sharp & Dohme LLC
Drug classnitroimidazole antibiotic
ModalitySmall molecule
Therapeutic areaGastrointestinal
PhasePhase 3

Mechanism of action

It does this by inhibiting the synthesis of DNA and RNA in these microorganisms, ultimately leading to their death. This is achieved through the disruption of the bacterial cell's ability to produce pyrimidine nucleotides, which are essential for DNA and RNA synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about placebo to metronidazole

What is placebo to metronidazole?

placebo to metronidazole is a nitroimidazole antibiotic drug developed by Merck Sharp & Dohme LLC, indicated for Amoebiasis, Bacterial vaginosis, Gastrointestinal infections.

How does placebo to metronidazole work?

Metronidazole is an antibiotic that works by stopping the growth of bacteria and protozoa.

What is placebo to metronidazole used for?

placebo to metronidazole is indicated for Amoebiasis, Bacterial vaginosis, Gastrointestinal infections, Pelvic inflammatory disease, Trichomoniasis.

Who makes placebo to metronidazole?

placebo to metronidazole is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What drug class is placebo to metronidazole in?

placebo to metronidazole belongs to the nitroimidazole antibiotic class. See all nitroimidazole antibiotic drugs at /class/nitroimidazole-antibiotic.

What development phase is placebo to metronidazole in?

placebo to metronidazole is in Phase 3.

What are the side effects of placebo to metronidazole?

Common side effects of placebo to metronidazole include Nausea, Diarrhea, Abdominal pain, Vaginal itching, Headache.

Related